Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed

Executive Summary

Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.

You may also be interested in...



Indian Trials Recover Amid Lingering Pandemic Challenges

The Indian clinical research segment has managed to retain some buoyancy despite pandemic-related disruptions, with an estimated 70 global trials cleared to October by the regulator. But audiovisual recording of the informed consent process has been particularly challenging in the case of subjects in isolation wards.

Pfizer Q1: Headwinds And Tailwinds From COVID-19

The company reaffirmed 2020 sales and earnings financial guidance, highlighting the resiliency of the business amid a global pandemic, but Pfizer did highlight some potential business challenges.

For Pfizer, Vaccines and Vyndaqel In The Q1 Spotlight

Earnings preview: Pfizer's newly launched rare disease drug Vyndaqel and vaccines could be impacted by COVID-19. Investors will also be eager to hear more about the timeline for closing the Upjohn transaction.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel